Sanofi or Iovance Biotherapeutics, Inc.: Who Manages SG&A Costs Better?

Managing SG&A Costs: Sanofi vs. Iovance Biotherapeutics, Inc.

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Sanofi and Iovance Biotherapeutics, Inc. have demonstrated contrasting approaches to SG&A cost management.

Sanofi, a global leader, consistently reported SG&A expenses around $10 billion annually, reflecting its expansive operations. In contrast, Iovance Biotherapeutics, Inc., a smaller biotech firm, showed a significant increase in SG&A expenses, rising from approximately $9 million in 2014 to over $100 million in 2023. This represents a staggering growth of over 1,000%, indicative of its aggressive expansion and investment in administrative capabilities.

While Sanofi's expenses remained stable, Iovance's rapid increase suggests a strategic focus on scaling operations. Understanding these trends provides valuable insights into how these companies prioritize their resources in a dynamic industry.